Weight change and lipoprotein particle concentration and particle size: A cohort study with 6.5-year follow-up

Atherosclerosis

Volumn 223, Issue 1, 2012, Pages 239-243

  Mäntyselkä, Pekka ^a,b   Kautiainen, Hannu ^b,c   Saltevo, Juha ^c   Würtz, Peter ^d,e   Soininen, Pasi ^a,e   Kangas, Antti J ^e   Ala Korpela, Mika ^a,e   Vanhala, Mauno ^a,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c Central Finland Central Hospital   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF OULU   (Finland)

Author keywords

Lipoprotein particle subclass; Population based study; Weight change

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PRIORITY JOURNAL; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; FINLAND; HUMANS; LINEAR MODELS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; LONGITUDINAL STUDIES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PARTICLE SIZE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; WEIGHT GAIN; WEIGHT LOSS;

EID: 84863099943     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.05.005     Document Type: Article

References (27)

1. Goldstein D.J. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992, 16:397-415.
2. Pi-Sunyer F.X. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 1996, 18:1006-1035.
3. Magkos F., Mohammed B.S., Mittendorfer B. Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women. Int J Obes (Lond) 2008, 32:1655-1664.
4. Stančáková A., Paananen J., Soininen P., Kangas A.J., Bonnycastle L.L., Morken M.A., et al. Effects of 34 risk loci for type 2 diabetes or hyperglycemia on lipoprotein subclasses and their composition in 6,580 nondiabetic Finnish men. Diabetes 2011, 60:1608-1616.
5. Cromwell W.C., Otvos J.D., Keyes M.J., Pencina M.J., Sullivan L., Vasan R.S., et al. LDL particle number and risk of future cardiovascular disease in the Framingham offspring study - implications for LDL management. J Clin Lipidol 2007, 1:583-592.
6. Mora S., Otvos J.D., Rifai N., Rosenson R.S., Buring J.E., Ridker P.M. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119:931-939.
7. Mora S., Otvos J.D., Rosenson R.S., Pradhan A., Buring J.E., Ridker P.M. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 2010, 59:1153-1160.
8. Krauss R.M. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol 2010, 21:305-311.
9. Siri-Tarino P.W., Williams P.T., Fernstrom H.S., Rawlings R.S., Krauss R.M. Reversal of small, dense LDL subclass phenotype by normalization of adiposity. Obes (Silver Spring) 2009, 17:1768-1775.
10. Naganuma R., Sakurai M., Miura K., Yoshita K., Morikawa Y., Kido T., et al. Relation of long-term body weight change to change in lipoprotein particle size in Japanese men and women: the INTERMAP Toyama study. Atherosclerosis 2009, 206:282-286.
11. Weiss R., Otvos J.D., Sinnreich R., Miserez A.R., Kark J.D. The triglyceride to high-density lipoprotein-cholesterol ratio in adolescence and subsequent weight gain predict nuclear magnetic resonance-measured lipoprotein subclasses in adulthood. J Pediatr 2011, 158:44-50.
12. Vanhala M., Kumpula L.S., Soininen P., Kangas A.J., Ala-Korpela M., Kautiainen H., et al. High serum adiponectin is associated with favorable lipoprotein subclass profile in 6.4-year follow-up. Eur J Endocrinol 2011, 164:549-552.
13. Ala-Korpela M. Critical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics. Clin Chem Lab Med 2008, 46:27-42.
14. Vehtari A., Makinen V.P., Soininen P., Ingman P., Mäkelä S.M., Savolainen M.J., et al. A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in 1H NMR metabonomic data. BMC Bioinform 2007, 8(Suppl. 2):S8.
15. Soininen P., Kangas A.J., Würtz P., Tukiainen T., Tynkkynen T., Laatikainen R., et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009, 134:1781-1785.
16. Tukiainen T., Kettunen J., Kangas A.J., Lyytikäinen L.P., Soininen P., Sarin A.P., et al. Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. Hum Mol Genet 2012, 21:1444-1455.
17. Okazaki M., Usui S., Ishigami M., Sakai N., Nakamura T., Matsuzawa Y., et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol 2005, 25:578-584.
18. Rivellese A.A., Patti L., Kaufman D., Zhu J., Annuzzi G., Vaccaro O., et al. Lipoprotein particle distribution and size, insulin resistance, and metabolic syndrome in Alaska Eskimos: the GOCADAN study. Atherosclerosis 2008, 200:350-358.
19. Goff D.C., D'Agostino R.B., Haffner S.M., Otvos J.D. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the insulin resistance atherosclerosis study. Metabolism 2005, 54:264-270.
20. Garvey W.T., Kwon S., Zheng D., Shaughnessy S., Wallace P., Hutto A., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003, 52:453-462.
21. Freedman D.S., Otvos J.D., Jeyarajah E.J., Barboriak J.J., Anderson A.J., Walker J.A. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998, 18:1046-1053.
22. Otvos J.D., Collins D., Freedman D.S., Shalaurova I., Schaefer E.J., McNamara J.R., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial. Circulation 2006, 113:1556-1563.
23. Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
24. Pascot A., Lemieux I., Prud'homme D., Tremblay A., Nadeau A., Couillard C., et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001, 42:2007-2014.
25. Arsenault B.J., Lemieux I., Després J.P., Gagnon P., Wareham N.J., Stroes E.S., et al. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Atherosclerosis 2009, 206:276-281.
26. Tirosh A., Shai I., Afek A., Dubnov-Raz G., Ayalon N., Gordon B., et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med 2011, 364:1315-1325.
27. Hardoon S.L., Morris R.W., Whincup P.H., Shipley M.J., Britton A.R., Masset G., et al. Rising adiposity curbing decline in the incidence of myocardial infarction: 20-year follow-up of British men and women in the Whitehall II cohort. Eur Heart J 2012, 33:478-485.